73 results about "Probenecid" patented technology

The invention relates to a medicinal composition for treating gout. The composition consists of febuxostat crystals, probenecid and a pharmaceutically acceptable medicinal carrier of which the ratio of part by weight is 1:10-200:0.05-100. When the ratio of the febuxostat crystals to the probenecid is 1 to 33.3, the inhibition ratio is improved by 155.6 percent compared with the total inhibition rate of the febuxostat crystals and the probenecid which are singly used; and when the ratio of the febuxostat crystals to the probenecid is 1 to 100, the inhibition ratio is improved by 113.3 percent compared with the total inhibition ratio of the febuxostat crystals and the probenecid which are singly used. Pharmacological tests show that the composition has obvious synergetic effect, can quickly reduce the concentration of uric acid in blood serum, obviously improves gout treatment effect, greatly reduces the dosage of each single component at the same time and effectively reduces the toxic and side effects of the medicament.

The present invention provides an inhalation-type pharmaceutical composition for gout and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising colchicine, allopurinol, probenecid, sulfinpyrazone, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

The invention relates to a Beta-lactam antibiotic compound preparation for animals, which contains probenecid. Calculated by weight percentage, the preparation is composed of 1 to 20 percent of probenecid , 5 to 20 percent of Beta-lactam antibiotic, 5 to 40 percent of cosolvent, and acceptable vector in pharmacy which is added until the preparation is 100 percent. The preparation can be orally administrated , and can be dissolved in water to be drunk by livestock and fowl. The invention has a broad antifungal spectrum, shows a strong antibacterial activity, is convenient to be used clinically, has good safety, and is applicable to treating light to moderate infection. The used practice shows that the preparation can reduce the dosage of the Beta-lactam antibiotic in clinical practice, can reduce the occurrence possibilities of drug resistance, and can also save the treatment cost with good using effect.

The invention discloses a probenecid purification method, comprising the steps of: reacting a crude probenecid product and an alkaline substance in water until the probenecid is dissolved completely; cooling an obtained solution to carry out low-temperature crystallization, and stirring till complete crystallization; filtering, dissolving the obtained filter cakes with water, and then, adding acid to regulate the obtained solution to be acidic; and filtering, washing the obtained filter cakes with water, and then filtering and drying to obtain a pure probenecid product. According to the invention, by utilization of chemical principles of crystallization and filtration, the purpose of purifying the probenecid in a water environment is achieved by alkaline dissolution and acidification operation. The probenecid purification method is simple to operate and free from utilization of organic solvents, so that the production cost and environment pollution are reduced greatly, and the requirement for clean production is met.

The present invention relates to a method for activation of TRPV2 (transient receptor potential vanilloid 2) using probenecid, more precisely a method for selecting a candidate for TRPV2 blocker using probenecid. Probenecid of the present invention works on TRPV2 specifically so that it facilitates the isolation of sensory neurons expressing TRPV2. Therefore, probenecid of the invention can be effectively used for the studies on TRPV2 mechanisms and the development of a TRPV2 based anodyne.

Described are inventions directed to methods of treating a cardiac dysfunction in a subject that includes administering an amount of probenecid effective to treat a symptom of cardiac dysfunction. The probenecid may be administered in at least one of an injection, orally, or transdermally. The amount of probenecid is sufficient to result in an improved performance on a standardized 6 minute walk test, an improved New York Heart Association (NYHA) classification, a lower diuretic dose requirement, a lower serum BNP levels, a normalization of serum sodium concentrations, and combinations thereof. In an embodiment, probenecid is administered over a period of about 8 hours to about 24 hours. Probenecid may be used for short term treatments, i.e., less than a week, or it may be administered in a long term manner, i.e., over a period of weeks, months, or even years.

The invention relates to a synthesis and preparation method for probenecid sodium and probenecid potassium. The method is characterized by comprising the following steps: heating water bath to reach 75 to 80 DEG C to completely dissolve probenecid in absolute ethyl alcohol; then dropping a mixed solution of sodium hydroxide or potassium hydroxide or absolute ethyl alcohol which is dissolved in advance at 70 DEG C at speed of 5ml per minute; further reacting for 15 minutes after dropping; slowly cooling to reach 50 to 60 DEG C; replacing a reflux condensing pipe by a distilling condensing pipe; heating the water bath to reach 90 to 95 DEG C; condensing until the volume is 1 / 5 of original volume; pouring out the reactant while hot; standing for more than 4 hours at cold condition; leaching to obtain rough products of probenecid sodium and probenecid potassium; and further refining to obtain the products probenecid sodium and probenecid potassium. According to the synthesis and preparation method, the absolute ethyl alcohol is adopted as the solvent, so that more crystals are separated after cooling when the reaction is finished, and the yield can reach over 80% after condensing; and the technical means for purifying and recrystallizing the probenecid sodium (potassium) is easy to operate, and suitable for industrial production.